Active Pharmaceutical Ingredients (API) Companies

The global active pharmaceutical ingredients market is projected to reach USD 198.39 billion by 2030 from USD 144.20 billion in 2025, at a CAGR of 6.6% from 2025 to 2030. The growth of the active pharmaceutical ingredients market is driven by the rising surge in demand for complex APIs, government incentives & supply chain reshoring, and increasing demand for APIs for novel formulation development.

Several key players in the active pharmaceutical ingredients industry with a strong global footprint include Pfizer (CentreOne) (US), Teva Pharmaceutical Industries Ltd. (Israel), Divi’s Laboratories Limited (India), Sandoz Group AG (Switzerland), SK Inc. (South Korea), Merck KGaA (Germany), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cipla (India), Aurobindo Pharma (India), Evonik Industries AG (Germany), Hikma Pharmaceuticals plc (UK), BASF SE (Germany), Alembic Pharmaceuticals Limited (India), Siegfried Holding AG (Switzerland), EUROAPI (France), Asymchem (China), Bachem (Switzerland), Zhejiang Huahai Pharmaceutical Co., Ltd. (China), and Zhejiang Hisun (China). Companies in this sector employ various growth strategies to strengthen their international presence and reinforce market positions like vertical integration, with pharma majors such as AbbVie, Pfizer, Novartis, and Sun Pharma producing APIs internally for control and reliability, and outsourcing, where firms partner with CDMOs such as Lonza, WuXi STA, and Divi’s Labs to leverage scale and expertise.

To know about the assumptions considered for the study download the pdf brochure

In December 2024, Novo Holdings reached an agreement to acquire Catalent for USD 16.5 billion. Although Catalent is a diversified CDMO, APIs and drug substance manufacturing are a significant part of its offering. The acquisition gives Novo Holdings more control over the drug substance value chain, including biologics APIs, and signals ongoing consolidation in the CDMO/API sector. In September 2024, AbbVie strengthened its US manufacturing footprint by confirming plans to build a new API plant in Illinois. This project is part of a broader USD 10 billion capital investment across AbbVie’s US sites, ensuring long-term supply security of key APIs. The facility will support commercial and clinical supply, especially for specialty and high-value therapies.

Pfizer Inc. (US)

Pfizer Inc. (US) is a global pharmaceutical leader and one of the pioneers in active pharmaceutical ingredients. As one of the largest pharmaceutical companies globally, Pfizer develops and produces both small-molecule APIs and biotech APIs to support its broad therapeutic portfolio, including oncology, vaccines, cardiovascular, and anti-infective treatments. The company has invested heavily in modernizing and expanding its API manufacturing infrastructure to enhance efficiency, regulatory compliance, and supply reliability. Recent expansions, such as the large-scale API facility in Singapore, reflect its focus on strengthening global production and reducing supply chain vulnerabilities. Pfizer also emphasizes sustainable manufacturing through greener chemistry and advanced process technologies. With increasing demand for high-potency APIs, Pfizer’s expertise, scale, and innovation place it at the forefront of shaping the evolving API market and meeting rising global healthcare needs.

Teva Pharmaceutical Industries Ltd. (Israel)

Teva Pharmaceuticals is one of the largest global players in the active pharmaceutical ingredients (API) market, supported by its dedicated subsidiary, Teva API. The company operates a broad network of manufacturing sites across Europe, North America, and Asia, producing over 350 APIs serving Teva’s generic portfolio and external customers worldwide. It is recognized for its leadership in high-quality, cost-effective generic APIs, as well as its capabilities in complex and high-potency molecules. The company invests in advanced process technologies, green chemistry, and regulatory compliance to maintain a competitive edge in a highly regulated market. By leveraging economies of scale, Teva ensures a reliable supply to global partners. Its diversified API portfolio, long-standing expertise, and a strong focus on innovation position Teva as a key enabler in meeting the growing global demand for affordable medicines.

Market Ranking

The active pharmaceutical ingredients market is characterized by intense fragmentation, with the top five key players commanding a minimal share of global revenues, estimated to be between 3% to 10% of the total market. These leading companies reinforce their market positions through strategic investments, regulatory advancements, and extensive partnerships. Pfizer Inc. (US) maintains a strong footprint in the API market through its extensive vertically integrated manufacturing network, ensuring supply security for critical therapies across oncology, vaccines, and rare diseases. The company continues to invest in next-generation API capabilities, particularly for complex injectables and biologics, while leveraging strategic partnerships to enhance global scale. Divi's Laboratories Limited (India), one of the world’s largest API producers, is a leading producer of cost-efficient APIs across therapeutic categories, supported by one of the industry’s broadest portfolios and a global distribution platform. Moreover, Asymchem (China) focuses on specialty and innovative APIs, with investments in oncology segments, complemented by sustainable chemistry initiatives to strengthen supply resilience and compliance with evolving regulatory standards. Cipla, Inc. (India) offers captive supply and third-party services, particularly in small-molecule and biologics APIs.

The active pharmaceutical ingredients (API) market is evolving swiftly, driven by investments in advanced manufacturing technologies, complex chemistry capabilities, and biologics production. Growing demand for generics, biosimilars, and specialty medicines is accelerating adoption, particularly as supply chain resilience and reshoring initiatives gain prominence in the US and Europe. Supportive regulatory frameworks, sustainability requirements, and strategic M&A activity are reshaping competitive dynamics, while partnerships with CDMOs expand global reach. With the rise of highly potent APIs, continuous manufacturing, and digital process optimization, the API market offers significant growth opportunities for established pharmaceutical leaders and specialized manufacturers.

The remainder of the market, comprising approximately 90%–97%, is populated by various regional and local players. These players are gaining ground through partnerships, collaborations, and technological innovation. Market shifts are driven by advances in pharmaceutical contract manufacturing, changing regulatory landscapes, and growing demand for non-invasive, personalized medicine.

Related Reports:

Active Pharmaceutical Ingredients (API) Market by type (Innovative, Generic), Synthesis (synthetic, biotech), Potency (HPAPI), Product (mAbs, hormones), Drug (OTC, Rx), Application (Diabetes, Oncology), Competitive landscape - Global forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com